{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:45:44Z","timestamp":1792907144544,"version":"4.5.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Autism spectrum disorders (ASD) are a group of disorders characterized by impairment in social communication and repetitive and stereotyped behaviors. ASD etiology is very complex, including the effect of both genetic and environmental factors. So far, no specific treatment for the core symptoms of ASD has been developed, although attempts have been made for the treatment of repetitive behavior. The pharmacological treatment is aimed at treating non-specific symptoms such as irritability and aggression. Recent studies pointed out to the possible role of altered dopamine signaling in mesocorticolimbic and nigrostriatal circuits in ASD. In addition, several research pointed out to the association of dopamine receptors polymorphism and ASD, specifically repetitive and stereotyped behavior. In this paper, we will provide a review of the studies regarding dopamine signaling in ASD, existing data on the effects of D2\/D3 partial agonists in ASD, possible implications regarding their individual receptor profiles, and future perspectives of their possible use in ASD treatment.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.787097","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:28:07Z","timestamp":1643873287000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":65,"title":["Dopamine in Autism Spectrum Disorders\u2014Focus on D2\/D3 Partial Agonists and Their Possible Use in Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Vanja","family":"Mandic-Maravic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Grujicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Milutinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Munjiza-Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Pejovic-Milovancevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pnpbp.2010.10.015","article-title":"Psychopharmacology in autism: an update","volume":"35","author":"Canitano","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6706a1","article-title":"Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014","volume":"67","author":"Baio","year":"2018","journal-title":"Morb Mortal Wkly report Surveill Summ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/jcm9040966","article-title":"Genetic and epigenetic etiology underlying autism spectrum disorder","volume":"9","author":"Yoon","year":"2020","journal-title":"J Clin Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaac.2013.10.013","article-title":"American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder","volume":"53","author":"Volkmar","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00213-013-3140-7","article-title":"Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care","volume":"231","author":"Murray","year":"2014","journal-title":"Psychopharmacology (Berl)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1542\/peds.2012-0900D","article-title":"Use of psychotropic medication in children and adolescents with autism spectrum disorders","volume":"130","author":"Coury","year":"2012","journal-title":"Pediatrics."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/acps.12644","article-title":"Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review","volume":"135","author":"Jobski","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"B8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fnins.2018.00304","article-title":"Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder","volume":"12","author":"Eissa","year":"2018","journal-title":"Front Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.rasd.2010.06.012","article-title":"Anxiety, depression, and irritability in children with autism relative to other neuropsychiatric disorders and typical development","volume":"5","author":"Mayes","year":"2011","journal-title":"Res Autism Spectr Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/ng.2711","article-title":"Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs","volume":"45","author":"Lee","year":"2013","journal-title":"Nat Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/09540261.2018.1458706","article-title":"An update on pharmacotherapy of autism spectrum disorder in children and adolescents","volume":"30","author":"Goel","year":"2018","journal-title":"Int Rev Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology","volume":"32","author":"Howes","year":"2018","journal-title":"J Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children","volume":"19","author":"Anderson","year":"1989","journal-title":"J Autism Dev Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J Autism Dev Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1089\/cap.2015.0005","article-title":"Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial","volume":"25","author":"Aman","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/B978-0-444-64012-3.00024-1","article-title":"The psychopharmacology of autism spectrum disorder and Rett syndrome","volume":"165","author":"Persico","year":"2019","journal-title":"Handb Clin Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"ADouble-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/WNF.0b013e31823349ac","article-title":"Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial","volume":"34","author":"Golubchik","year":"2011","journal-title":"Clin Neuropharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1089\/cap.2016.0049","article-title":"Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder","volume":"26","author":"Yoon","year":"2016","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.neuroscience.2014.10.008","article-title":"The place of dopamine in the cortico-basal ganglia circuit","volume":"282","author":"Haber","year":"2014","journal-title":"Neuroscience."},{"key":"B21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000478725","article-title":"Dopamine hypothesis of autism spectrum disorder","volume":"39","author":"Pav\u0103l","year":"2017","journal-title":"Dev Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg-Martin","year":"2010","journal-title":"Neuron."},{"key":"B23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fnins.2013.00233","article-title":"The role of the striatum in social behavior","volume":"7","author":"B\u00e1ez-Mendoza","year":"2013","journal-title":"Front Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1866-1955-4-19","article-title":"Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings","volume":"4","author":"Dichter","year":"2012","journal-title":"J Neurodev Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbr.2006.08.023","article-title":"Animal models of restricted repetitive behavior in autism","volume":"176","author":"Lewis","year":"2007","journal-title":"Behav Brain Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tics.2012.02.007","article-title":"The social motivation theory of autism","volume":"16","author":"Chevallier","year":"2012","journal-title":"Trends Cogn Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.biopsych.2006.07.021","article-title":"Neural correlates of social cooperation and non-cooperation as a function of psychopathy","volume":"61","author":"Rilling","year":"2007","journal-title":"Biol Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.cell.2014.05.017","article-title":"Natural neural projection dynamics underlying social behavior","volume":"157","author":"Gunaydin","year":"2014","journal-title":"Cell."},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/brainsci10030163","article-title":"The neurochemistry of autism","volume":"10","author":"Marotta","year":"2020","journal-title":"Brain Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/aur.122","article-title":"Reward processing in autism","volume":"3","author":"Scott-Van Zeeland","year":"2010","journal-title":"Autism Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1074\/jbc.RA118.001753","article-title":"Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes","volume":"293","author":"Herborg","year":"2018","journal-title":"J Biol Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1172\/JCI127411","article-title":"Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors","volume":"129","author":"DiCarlo","year":"2019","journal-title":"J Clin Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/brainsci10040233","article-title":"P-cresol alters brain dopamine metabolism and exacerbates autism-like behaviors in the BTBR mouse","volume":"10","author":"Pascucci","year":"2020","journal-title":"Brain Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13041-020-00649-7","article-title":"Altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism","volume":"13","author":"Chao","year":"2020","journal-title":"Mol Brain."},{"key":"B35","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0091-3057(02)01081-X","article-title":"Selective blockade of spontaneous motor stereotypy via intrastriatal pharmacological manipulation","volume":"74","author":"Presti","year":"2003","journal-title":"Pharmacol Biochem Behav."},{"key":"B36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.phrs.2018.12.001","article-title":"A fresh look at cortical dopamine D2 receptor expressing neurons","volume":"139","author":"Quintana","year":"2019","journal-title":"Pharmacol Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.coph.2008.12.002","article-title":"Getting specialized: presynaptic and postsynaptic dopamine D2 receptors","volume":"9","author":"De Mei","year":"2009","journal-title":"Curr Opin Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/cercor\/bhn134","article-title":"Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"19","author":"Santana","year":"2009","journal-title":"Cereb Cortex."},{"key":"B39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145799001431","article-title":"Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET","volume":"2","author":"Suhara","year":"1999","journal-title":"Int J Neuropsychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"577858","DOI":"10.3389\/fncel.2020.577858","article-title":"Increased dopamine Type 2 gene expression in the dorsal striatum in individuals with autism spectrum disorder suggests alterations in indirect pathway signaling and circuitry","volume":"14","author":"Brandenburg","year":"2020","journal-title":"Front Cell Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00213-011-2340-2","article-title":"Human cognitive flexibility depends on dopamine D2 receptor signaling","volume":"218","author":"van Holstein","year":"2011","journal-title":"Psychopharmacology (Berl)."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/npp.2016.22","article-title":"Dopaminergic neurotransmission in the nucleus accumbens modulates social play behavior in rats","volume":"41","author":"Manduca","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","article-title":"Dopamine D(3) receptor as a new pharmacological target for the treatment of depression","volume":"719","author":"Leggio","year":"2013","journal-title":"Eur J Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/biom11010104","article-title":"Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders","volume":"11","author":"Kiss","year":"2021","journal-title":"Biomolecules"},{"key":"B45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fphar.2015.00297","article-title":"Dopamine D3 receptors inhibit hippocampal gamma oscillations by disturbing CA3 pyramidal cell firing synchrony","volume":"6","author":"Lemercier","year":"2016","journal-title":"Front Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"108099","DOI":"10.1016\/j.neuropharm.2020.108099","article-title":"Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: focus on 5-HT6 and D3 receptors as hubs","volume":"177","author":"Millan","year":"2020","journal-title":"Neuropharmacology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S1461145711000435","article-title":"Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment","volume":"15","author":"Watson","year":"2012","journal-title":"Int J Neuropsychopharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.euroneuro.2015.12.020","article-title":"The dopamine D3-preferring D2\/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia","volume":"26","author":"Watson","year":"2016","journal-title":"Eur Neuropsychopharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1192\/bjp.bp.114.148973","article-title":"DRD3 gene and striatum in autism spectrum disorder","volume":"206","author":"Staal","year":"2015","journal-title":"Br J Psychiatry."},{"key":"B50","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.biopsych.2008.09.035","article-title":"A common variant in DRD3 receptor is associated with autism spectrum disorder","volume":"65","author":"de Krom","year":"2009","journal-title":"Biol Psychiatry."},{"key":"B51","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3109\/15622975.2011.602719","article-title":"Neurotransmitter systems and neurotrophic factors in autism: association study of 37 genes suggests involvement of DDC","volume":"14","author":"Toma","year":"2013","journal-title":"World J Biol Psychiatry."},{"key":"B52","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc","year":"2015","journal-title":"P T"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, a drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr Neuropharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"CD009043","DOI":"10.1002\/14651858.CD009043.pub3","article-title":"Aripiprazole for autism spectrum disorders (ASD)","volume":"2016","author":"Hirsch","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.2147\/NDT.S174622","article-title":"Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: a systematic review and meta-analysis","volume":"14","author":"Maneeton","year":"2018","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B56","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12888-021-03201-6","article-title":"Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance","volume":"21","author":"Sugimoto","year":"2021","journal-title":"BMC Psychiatry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1517\/14656566.2011.557661","article-title":"Aripiprazole for the treatment of irritability associated with autism","volume":"12","author":"Farmer","year":"2011","journal-title":"Expert Opin Pharmacother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"A222","DOI":"10.1016\/j.jval.2014.03.1300","article-title":"Use of aripiprazole and risperidone in children with autism: Effects of introducing an alternative new patented drug and debuting the first generic drug","volume":"17","author":"Wang","year":"2014","journal-title":"Value Heal."},{"key":"B59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40272-016-0183-3","article-title":"Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD: a pilot, open-label, randomized controlled study","volume":"18","author":"Lamberti","year":"2016","journal-title":"Paediatr Drugs."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00213-021-05851-6","article-title":"Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder","volume":"238","author":"Rom\u00e1n","year":"2021","journal-title":"Psychopharmacology (Berl)."},{"key":"B61","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1124\/jpet.119.259879","article-title":"The Role of Dopamine D(3) receptor partial agonism in cariprazine-induced neurotransmitter efflux in rat hippocampus and nucleus accumbens","volume":"371","author":"Huang","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neubiorev.2016.07.025","article-title":"The neurobiology of social play and its rewarding value in rats","volume":"70","author":"Vanderschuren","year":"2016","journal-title":"Neurosci Biobehav Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data","volume":"10","author":"Stahl","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology (Berl)."},{"key":"B65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/cap.2019.0106","article-title":"Cariprazine in youth with bipolar and psychotic disorders: a retrospective chart review","volume":"30","author":"Poweleit","year":"2020","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fpsyt.2020.00061","article-title":"Cariprazine safety in adolescents and the elderly: analyses of clinical study data","volume":"11","author":"Szatm\u00e1ri","year":"2020","journal-title":"Front Psychiatry."},{"key":"B67","article-title":"Lumateperone","volume-title":"StatPearls","author":"Cooper","year":"2021"},{"key":"B68","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology (Berl)."},{"key":"B69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuint.2019.04.008","article-title":"Blonanserin ameliorates social deficit through dopamine-D(3) receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia","volume":"128","author":"Takeuchi","year":"2019","journal-title":"Neurochem Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","article-title":"Dopamine D3 receptor antagonism\u2014still a therapeutic option for the treatment of schizophrenia","volume":"386","author":"Gross","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e2885","DOI":"10.1002\/jmr.2885","article-title":"Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D(3) dopamine receptor over D(2) dopamine receptor","volume":"34","author":"Appiah-Kubi","year":"2021","journal-title":"J Mol Recognit."},{"key":"B72","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/ph13110365","article-title":"Dopamine, cognitive impairments and second-generation antipsychotics: from mechanistic advances to more personalized treatments","volume":"13","author":"Torrisi","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"173635","DOI":"10.1016\/j.ejphar.2020.173635","article-title":"Pharmacology profile of F17464, a dopamine D(3) receptor preferential antagonist","volume":"890","author":"Cosi","year":"2021","journal-title":"Eur J Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","article-title":"Dopamine serotonin stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder","volume":"189","author":"Cantillon","year":"2017","journal-title":"Schizophr Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/cts.12545","article-title":"Initial clinical experience of RP5063 following single doses in normal healthy volunteers and multiple doses in patients with stable schizophrenia","volume":"11","author":"Cantillon","year":"2018","journal-title":"Clin Transl Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"B77","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2967\/jnumed.110.081885","article-title":"Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812","volume":"52","author":"Catafau","year":"2011","journal-title":"J Nucl Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"N\u00e9meth","year":"2017","journal-title":"Lancet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fpsyt.2020.00548","article-title":"Autism spectrum disorder and schizophrenia are better differentiated by positive symptoms than negative symptoms","volume":"11","author":"Trevisan","year":"2020","journal-title":"Front Psychiatry"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/aur.1977","article-title":"Association between schizophrenia and autism spectrum disorder: A systematic review and meta-analysis","volume":"11","author":"Zheng","year":"2018","journal-title":"Autism Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10803-015-2539-x","article-title":"Re-conceptualizing ASD within a dimensional framework: positive, negative, and cognitive feature clusters","volume":"46","author":"Foss-Feig","year":"2016","journal-title":"J Autism Dev Disord"},{"key":"B82","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1017\/S003329170999078X","article-title":"Comparison of social cognitive functioning in schizophrenia and high functioning autism: more convergence than divergence","volume":"40","author":"Couture","year":"2010","journal-title":"Psychol Med"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.787097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:28:10Z","timestamp":1643873290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.787097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":82,"alternative-id":["10.3389\/fpsyt.2021.787097"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.787097","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"article-number":"787097"}}